CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 314 enrolled
Drug / intervention
5-mg Desloratadine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00536380
NCT00536380Phase 4Completed
CompareCT.gov

A Study of the Efficacy, Safety, and Quality of Life (QOL) in Patients With Chronic Idiopathic Urticaria Dosed With AERIUS Tablets (Desloratadine 5 mg, 10 mg, or 20 mg Once Daily)

Organon and Co·interventional·Posted Sep 27, 2007·Updated May 23, 2024

In Brief

A Phase 4 clinical trial evaluating 5-mg Desloratadine, 10-mg Desloratadine, and 1 other intervention for Chronic Idiopathic Urticaria. Completed, enrolled 314 participants.

Detailed Summary

This study will investigate the effectiveness of desloratadine at doses higher (10 mg and 20 mg) than currently approved (5 mg) for the treatment of chronic idiopathic urticaria. Subjects with chronic urticaria who are currently taking a second generation antihistamine will be treated with desloratadine (5, 10, or 20 mg) for 28 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Idiopathic Urticaria
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 27, 2007
Enrollment StartSep 1, 2007
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 18.8 years ago

Interventions

5-mg Desloratadinedrug

5-mg desloratadine tablets, once daily for four weeks.

10-mg Desloratadinedrug

10-mg desloratadine tablets, once daily for four weeks.

20-mg Desloratadinedrug

20-mg desloratadine tablets, once daily for four weeks.